Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | HTR1D | P28221 | 8/20 | 0.51 |
| ▸ | HTR6 | P50406 | 3/20 | 0.49 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20614497 | 0.88 | HTR1D (0.62) | HTR2CHTR2AHTR1DHTR6NOS3 | |
| SCHEMBL23612448 | 0.81 | ACACB (0.46) | HTR2CHTR2AHTR7 | |
| SCHEMBL16939364 | 0.80 | HTR2C (0.63) | HTR2CHTR2AHTR1DHTR6NOS3 | |
| SCHEMBL15701642 | 0.79 | CYP19A1 (0.52) | HTR2CHTR2AHTR6HTR7 | |
| SCHEMBL20540198 | 0.78 | HTR2C (0.61) | HTR2CHTR2AHTR1DHTR6NOS3 | |
| SCHEMBL14016155 | 0.78 | HTR2C (0.61) | HTR2CHTR2AHTR1DHTR6NOS3 | |
| SCHEMBL30411128 | 0.78 | HTR2C (0.61) | HTR2CHTR2AHTR1DHTR6NOS3 | |
| SCHEMBL23956081 | 0.78 | HTR2A (0.69) | HTR2CHTR2AHTR1DHTR6NOS3 | |
| SCHEMBL6597437 | 0.78 | HTR2C (0.61) | HTR2CHTR2AHTR1DHTR6NOS3 | |
| SCHEMBL216229 | 0.78 | HTR2C (0.61) | HTR2CHTR2AHTR1DHTR6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HTR2C 1579/4885HTR2A 3266/4885HTR1D 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.